Pancreatic ductal adenocarcinoma kills roughly 90 percent of patients within five years, and the survival curve for metastatic disease barely budges even with modern chemotherapy combinations. Against that backdrop, Theriva Biologics dosed the first patient in VIRAGE2 on August 6, 2026, a Phase 2a proof-of-concept study asking a sharper question than its predecessor: what happens when you give VCN-01 (zabilugene almadenorepvec) more frequently in the first-line metastatic setting, layered on top of gemcitabine/nab-paclitaxel chemotherapy.
The trial’s lineage matters here. The earlier VIRAGE Phase 2b program (NCT05673811) tested VCN-01 in the same patient population and same chemotherapy backbone, generating survival data that gave Theriva enough signal to press forward. VIRAGE2 is not a pivot or a redesign; it is a deliberate escalation of the dosing hypothesis. Oncolytic adenoviruses like VCN-01 work partly by replicating within tumor cells, disrupting the dense stromal barrier that makes PDAC so resistant to systemic therapy. The premise of VIRAGE2 is that repeated dosing could sustain that disruption across treatment cycles rather than delivering a single viral pulse. Whether the immune response blunts subsequent doses, or whether cumulative viral exposure amplifies tumor infiltration, is precisely what a small proof-of-concept study is designed to resolve before committing to a larger randomized trial.
The competitive context is real. The FDA approved NALIRIFOX in February 2024 for first-line metastatic pancreatic adenocarcinoma, adding a viable alternative to gemcitabine/nab-paclitaxel. That approval confirms the regulatory pathway is functional in this disease, and it raises the response-rate threshold any combination regimen needs to clear to justify clinical and commercial development. Theriva is not competing with a chemotherapy doublet in a vacuum; it is trying to demonstrate that an oncolytic virus adds measurable benefit on top of regimens that oncologists are already adopting.
VIRAGE2 is a small study, explicitly described as proof-of-concept, so the data it generates will be hypothesis-confirming or hypothesis-killing rather than registration-enabling. The one number to track from this trial is the objective response rate at the more frequent dosing schedule compared to the historical VIRAGE signal. If that figure moves meaningfully upward, Theriva has the dose-optimization rationale it needs to design a credible Phase 2b or Phase 3 follow-on. If it does not, the dosing strategy gets retired and the broader VCN-01 program faces a harder conversation about what comes next.
Source link: https://www.sec.gov/Archives/edgar/data/894158/000110465926091674/tm2622359d1_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
